ÖZET
Kemiğin Paget hastalığı, genellikle radyolojik incelemelerde tesadüfen tespit edilen kronik fokal kemik yapılanma bozukluğu ile karakterizedir. Her ne kadar serum total alkalen fosfataz Paget hastalığında genel bir kemik döngüsü belirteci olsa da, hastaların yaklaşık %10-15’inde referans aralığında bulunur. Semptomatik formların tedavisi, kemik döngüsündeki yükselmeleri azaltmakta etkili olan bifosfonatlar ile sağlanır. Burada kronik bel ağrısı olan ve normal serum alkalen fosfataz ve kemik spesifik alkalen fosfataz düzeyleri ile Paget hastalığı tanısı alan 80 yaşında bir olgu sunulmaktadır.
References
1
Corral-Gudino L, Borao-Cengotita-Bengoa M, Del Pino-Montes J, Ralston SH. Epidemiology of Paget’s disease of bone: a systematic review and meta-analysis of secular changes. Bone 2013;55:347-52.
2
Teramachi J, Nagata Y, Mohammad K, Inagaki Y, Ohata Y, Guise T, et al. Measles virus nucleocapsid protein increases osteo blast differentiation in Paget’s disease. J Clin Invest 2016;126:1012-22.
3
Visconti MR, Usategui-Martin R, Ralston SH. Antibody response to paramyxoviruses in Paget’s disease of bone. Calcif Tissue Int 2017;101:141-7.
4
Tuck SP, Layfield R, Walker J, Mekkayil B, Francis R. Adult Paget’s disease of bone: a review. Rheumatology (Oxford) 2017;56:2050-9.
5
Britton C, Brown S, Ward L, Rea SL, Ratajczak T, Walsh JP. The Changing Presentation of Paget’s Disease of Bone in Australia, A High Prevalence Region. Calcif Tissue Int 2017;101:564-9.
6
Kelepouris N, Schur PH, Drezner MK, Romain PL. Clinical manifestations and diagnosis of Paget disease of bone. In: UpToDate, Basow,DS (Ed), UpToDate, Waltham, MA, 2010.
7
Bezza A. Sacro-iliac involvement in the course of Paget disease. Report of 6 cases. Presse Med 1999;28:1157-9.
8
Roudsari JM, Mahjoub S. Quantification and comparison of bone-specific alkaline phosphatase with two methods in normal and paget’s specimens. Caspian J Intern Med 2012;3:478-83.
9
Eekhoff ME, van der Klift M, Kroon HM, Cooper C, Hofman A, Pols HA, et al. Paget’s disease of bone in the Netherlands: a population-based radiological and biochemical survey - the Rotterdam Study. J Bone Miner Res 2004;19;566-70.
10
Alvarez L, Guanabens N, Peris P, Monegal A, Bedini JL, Deulofeu R, et al. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget’s disease. J Bone Miner Res 1995;10;458-65.
11
Wu LC, Tseng CH, Chiang YF, Tsuang YH. Monostotic vertebral Paget’s disease of the lumbar spine. J Chin Med Assoc 2009;72:52-5.
12
Skeletal metastases. In: Resnick-Kransdorf, editors. Bone and joint imaging, (3th eds). Elsevier Saunders 2005:1245-64.
13
Bolland MJ, Cundy T. Paget’s disease of bone: clinical review and update. Postgrad Med J 2014;90:328-31.
14
Bolland MJ, Cundy T. Paget’s disease of bone: clinical review and update. J Clin Pathol 2013;66:924-7.
15
Corral-Gudino L, Tan AJ, Del Pino-Montes J, Ralston SH. Bisphosphonates for Paget’s disease of bone in adults. Cochrane Database Syst Rev 2017;12:CD004956.
16
Singer FR, Bone HG 3rd, Hosking DJ, Lyles KW, Murad MH, Reid IR, et al. Paget’s disease of bone: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014;99;4408-22.
17
Hosking D, Lyles K, Brown JP, Fraser WD, Miller P, Curiel MD, et al. Long-term control of bone turnover in Paget’s disease with zoledronic acid and risedronate. J Bone Miner Res 2007;22:142-8.
18
Reid IR, Lyles K, Su G, Brown JP, Walsh JP, del Pino-Mortes J, et al. A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years. J Bone Miner Res 2011;26:2261-70.
19
Reid IR, Sharma S, Kalluru R, Eagleton C. Treatment of Paget’s disease of bone with denosumab:case report and literature review. Calcif Tissue Int 2016;99:322-5.
20
Hirao M, Hashimoto J. Denosumab as the potent therapeutic agent against Paget’s disease of the bone. Clin Calcium 2011;21;1231-8.
21
Griz L, Caldas G, Bandeira C, Assunção V, Bandeira F. Paget’s disease of bone. Arq Bras Endocrinol Metab 2006;50:814-22.
